Oncolytics Biotech (ONCY) Research & Development (2009 - 2025)

Oncolytics Biotech (ONCY) has 17 years of Research & Development data on file, last reported at $5.5 million in Q3 2025.

• On a quarterly basis, Research & Development rose 9.64% year-over-year to $5.5 million in Q3 2025; TTM through Sep 2025 was $13.6 million, a 15.03% decrease from a year earlier, with the FY2025 full-year figure at $13.3 million, down 13.79% from the prior year.
• Research & Development for Q3 2025 stood at $5.5 million, up from $2.0 million in the prior quarter.
• Over the last five years, Research & Development for ONCY reached as high as $5.5 million in Q3 2025 and fell as low as $2.0 million in Q2 2025.
• Historically, Research & Development has averaged $3.2 million across 5 years, with a median of $2.9 million in 2021.
• Across the five-year window, Research & Development surged 62.81% in 2024 and tumbled 39.17% in 2025, its largest moves.
• Year by year, Research & Development stood at $2.9 million in 2021, then rose by 22.21% to $3.6 million in 2022, then decreased by 4.08% to $3.4 million in 2023, then slipped by 4.76% to $3.3 million in 2024, then surged by 67.58% to $5.5 million in 2025.
• Per Business Quant data, the three most recent Research & Development figures were $5.5 million in Q3 2025, $2.0 million in Q2 2025, and $2.8 million in Q1 2025.